Compass Therapeutics Investor Presentation Deck

CTX-471 Clinical Development Plans Phase 1b study fully enrolled Generally well tolerated Four partial responses as a monotherapy agent in the post PD-1/PD-L1 patient population Small cell lung cancer, mesothelioma, and melanoma (two patients) COMPASS THERAPEUTICS Initiating Phase 1b of CTX-471 with KeytrudaⓇ Abbreviated CTX-471 dose escalation into the PD-1 regimen, followed by a cohort expansion Post PD-1/PD-L1 Salvage Study Clinical collaboration with Merck 32

View entire presentation